These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1235 related items for PubMed ID: 16884968

  • 1. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 2. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K.
    J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
    [Abstract] [Full Text] [Related]

  • 3. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 5. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 25; 82(18):1254-6. PubMed ID: 12425805
    [Abstract] [Full Text] [Related]

  • 6. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr 25; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 7. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 25; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 8. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R, Krege JH, Chen P, Glass EV, Reginster JY.
    Curr Med Res Opin; 2006 Jan 25; 22(1):61-6. PubMed ID: 16393431
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 25; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 10. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 25; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 25; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 12. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 25; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 13. PINP as an aid for monitoring patients treated with teriparatide.
    Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH.
    Bone; 2011 Apr 01; 48(4):798-803. PubMed ID: 21168536
    [Abstract] [Full Text] [Related]

  • 14. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr 01; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 15. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec 01; 14(80):207-11. PubMed ID: 16397977
    [Abstract] [Full Text] [Related]

  • 16. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
    Middleton ET, Steel SA, Doherty SM.
    Calcif Tissue Int; 2007 Nov 01; 81(5):335-40. PubMed ID: 17938845
    [Abstract] [Full Text] [Related]

  • 17. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug 01; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 18. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep 01; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 19. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 01; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 01; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.